Department of Cardiovascular Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Department of Cardiovascular Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Microvasc Res. 2022 Jul;142:104368. doi: 10.1016/j.mvr.2022.104368. Epub 2022 Apr 1.
Studies have probed the function of microRNA (miR)-16-5p in the progression of atherosclerosis (AS), while the regulatory function of exosomal miR-16-5p from macrophage on AS remains largely unknown. This study commits to exploring the efficiency of exosomal miR-16-5p from macrophage on AS via modulating mothers against decapentaplegic homolog 7 (SMAD7).
Macrophages were cultured and transfected with miR-16-5p antagomir, then, the exosomes from macrophages were extracted. The AS mouse model was established, and miR-16-5p or SMAD7 expression in AS mice was detected. Thereafter, the effects of macrophage-derived exosomes, miR-16-5p or SMAD7 on serum inflammatory response, oxidative stress response, pathological changes and apoptosis in AS mice were observed by immunohistochemical and biochemical analysis. Finally, the binding relation between miR-16-5p and SMAD7 was examined.
MiR-16-5p was elevated while SMAD7 was depleted in AS mice. Macrophage-derived exosomes aggravated AS progression via facilitating inflammatory response and oxidative stress, exacerbating pathological changes and increasing cell apoptosis in AS mice; while downregulation of miR-16-5p reversed the exacerbation of AS progression by macrophage-derived exosomes in AS mice. MiR-16-5p targeted SMAD7, and the down-regulated SMAD7 reversed the impacts of depleted miR-16-5p on AS progression.
Exosomal miR-16-5p from macrophages aggravates AS progression via downregulating SMAD7 expression. This study provides novel therapeutic targets for AS treatment from the animal level.
已有研究探讨了微小 RNA(miR)-16-5p 在动脉粥样硬化(AS)进展中的作用,而巨噬细胞来源的外泌体 miR-16-5p 对 AS 的调控作用在很大程度上尚不清楚。本研究旨在通过调节母亲抗凋亡蛋白 7(SMAD7)来探讨巨噬细胞来源的外泌体 miR-16-5p 对 AS 的作用效率。
培养巨噬细胞并转染 miR-16-5p 拮抗剂,然后提取巨噬细胞来源的外泌体。建立 AS 小鼠模型,检测 AS 小鼠中 miR-16-5p 和 SMAD7 的表达。然后,通过免疫组化和生化分析观察巨噬细胞来源的外泌体、miR-16-5p 或 SMAD7 对 AS 小鼠血清炎症反应、氧化应激反应、病理变化和细胞凋亡的影响。最后,检测 miR-16-5p 与 SMAD7 的结合关系。
AS 小鼠中 miR-16-5p 升高而 SMAD7 减少。巨噬细胞来源的外泌体通过促进炎症反应和氧化应激、加重 AS 小鼠的病理变化和增加细胞凋亡,加重 AS 进展;而下调 miR-16-5p 可逆转巨噬细胞来源的外泌体对 AS 小鼠进展的加重作用。miR-16-5p 靶向 SMAD7,下调 SMAD7 逆转了 miR-16-5p 耗竭对 AS 进展的影响。
巨噬细胞来源的外泌体 miR-16-5p 通过下调 SMAD7 表达加重 AS 进展。本研究从动物水平为 AS 治疗提供了新的治疗靶点。